A2A-D2 Heteromers on Striatal Astrocytes: Biochemical and Biophysical Evidence.
A2A-D2 heteromers
co-immunoprecipitation
proximity ligation assay
rat striatum
striatal astrocyte processes
striatal slices
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
17 May 2019
17 May 2019
Historique:
received:
15
04
2019
revised:
14
05
2019
accepted:
16
05
2019
entrez:
22
5
2019
pubmed:
22
5
2019
medline:
13
11
2019
Statut:
epublish
Résumé
Our previous findings indicate that A2A and D2 receptors are co-expressed on adult rat striatal astrocytes and on the astrocyte processes, and that A2A-D2 receptor⁻receptor interaction can control the release of glutamate from the processes. Functional evidence suggests that the receptor⁻receptor interaction was based on heteromerization of native A2A and D2 receptors at the plasma membrane of striatal astrocyte processes. We here provide biochemical and biophysical evidence confirming that receptor⁻receptor interaction between A2A and D2 receptors at the astrocyte plasma membrane is based on A2A-D2 heteromerization. To our knowledge, this is the first direct demonstration of the ability of native A2A and D2 receptors to heteromerize on glial cells. As striatal astrocytes are recognized to be involved in Parkinson's pathophysiology, the findings that adenosine A2A and dopamine D2 receptors can form A2A-D2 heteromers on the astrocytes in the striatum (and that these heteromers can play roles in the control of the striatal glutamatergic transmission) may shed light on the molecular mechanisms involved in the pathogenesis of the disease.
Identifiants
pubmed: 31109007
pii: ijms20102457
doi: 10.3390/ijms20102457
pmc: PMC6566402
pii:
doi:
Substances chimiques
Receptor, Adenosine A2A
0
Receptors, Dopamine D2
0
Glutamic Acid
3KX376GY7L
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Déclaration de conflit d'intérêts
The authors declare no conflict of interest. The funding sources had no involvement in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.
Références
J Neurochem. 2004 Feb;88(3):726-34
pubmed: 14720222
Parkinsonism Relat Disord. 2004 Jul;10(5):265-71
pubmed: 15196504
Anal Chem. 2004 Sep 15;76(18):5354-63
pubmed: 15362892
Curr Protein Pept Sci. 2006 Feb;7(1):3-15
pubmed: 16472166
J Neural Transm (Vienna). 2007 Jan;114(1):49-75
pubmed: 17066251
J Proteome Res. 2006 Nov;5(11):3077-83
pubmed: 17081059
Brain Res Rev. 2007 Aug;55(1):119-33
pubmed: 17408566
Brain Res Rev. 2007 Aug;55(1):167-89
pubmed: 17467058
Mov Disord. 2007 Oct 31;22(14):1990-2017
pubmed: 17618524
J Neurochem. 2009 Jun;109(5):1497-507
pubmed: 19344374
J Med Chem. 2009 Sep 24;52(18):5590-602
pubmed: 19711895
Prog Neurobiol. 2010 Feb 9;90(2):157-75
pubmed: 19850102
Neurochem Res. 2010 Oct;35(10):1628-34
pubmed: 20596769
Neuroscience. 2010 Sep 29;170(1):67-77
pubmed: 20620192
Curr Top Med Chem. 2011;11(8):1034-46
pubmed: 21401497
Biotechniques. 2011 Aug;51(2):111-8
pubmed: 21806555
Pharmacol Ther. 2011 Dec;132(3):280-99
pubmed: 21810444
CNS Neurol Disord Drug Targets. 2011 Sep 1;10(6):659-69
pubmed: 21838670
J Neurosci. 2013 Jul 10;33(28):11390-9
pubmed: 23843511
Neurobiol Dis. 2014 Sep;69:206-14
pubmed: 24892887
Curr Protein Pept Sci. 2014;15(7):703-18
pubmed: 25175453
Expert Opin Ther Targets. 2015 Feb;19(2):265-83
pubmed: 25381716
Expert Opin Ther Targets. 2015 Mar;19(3):377-98
pubmed: 25486101
J Med Chem. 2015 Jan 22;58(2):718-38
pubmed: 25490054
Rev Neurosci. 2015;26(5):489-506
pubmed: 26103627
Neuropharmacology. 2015 Dec;99:396-407
pubmed: 26260232
Front Neuroanat. 2015 Sep 25;9:117
pubmed: 26441550
Annu Rev Pharmacol Toxicol. 2016;56:403-25
pubmed: 26514203
Neuromolecular Med. 2016 Mar;18(1):50-68
pubmed: 26530396
J Neurochem. 2016 Mar;136(5):1004-16
pubmed: 26576509
J Neuroinflammation. 2016 Feb 26;13:48
pubmed: 26920550
Front Pharmacol. 2016 Mar 31;7:76
pubmed: 27065866
PLoS One. 2016 May 17;11(5):e0155759
pubmed: 27186643
Glia. 2016 Sep;64(9):1465-78
pubmed: 27301342
J Neurochem. 2016 Oct;139 Suppl 1:325-337
pubmed: 27577098
J Neurochem. 2017 Jan;140(2):268-279
pubmed: 27896809
Curr Protoc Pharmacol. 2016 Dec 13;75:2.16.1-2.16.31
pubmed: 27960030
Trends Neurosci. 2017 Jun;40(6):358-370
pubmed: 28527591
Ann N Y Acad Sci. 1985;448:315-33
pubmed: 2862827
Front Pharmacol. 2018 Jan 04;8:924
pubmed: 29354053
Neurotherapeutics. 2018 Jul;15(3):796-806
pubmed: 29435814
Rev Neurosci. 2018 Sep 25;29(7):703-726
pubmed: 29466243
Neuroscience. 2018 May 1;377:184-196
pubmed: 29544901
Neural Regen Res. 2018 Feb;13(2):241-243
pubmed: 29557372
Med Res Rev. 1985 Oct-Dec;5(4):441-82
pubmed: 2999530
J Mol Neurosci. 2018 Aug;65(4):456-466
pubmed: 30030763
Front Synaptic Neurosci. 2018 Jul 10;10:20
pubmed: 30042672
Front Pharmacol. 2018 Aug 30;9:829
pubmed: 30214407
Front Endocrinol (Lausanne). 2019 Feb 18;10:53
pubmed: 30833931
Med Biol. 1980 Aug;58(4):182-7
pubmed: 6167826
J Neural Transm Suppl. 1983;18:165-79
pubmed: 6192208
Proc Natl Acad Sci U S A. 1982 Jun;79(12):3739-43
pubmed: 6285362
Biochem Biophys Res Commun. 1982 Nov 16;109(1):21-9
pubmed: 6297476
Glia. 1993 Sep;9(1):48-56
pubmed: 7902337
Int J Neural Syst. 1996 Sep;7(4):363-8
pubmed: 8968825
Anal Biochem. 1976 May 7;72:248-54
pubmed: 942051